14-烷基氨基和 14-烷氧基-4,5-环氧吗啡烷衍生物的最新发展和修饰。
Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivatives.
机构信息
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA.
出版信息
Mini Rev Med Chem. 2011 Oct;11(12):1002-8. doi: 10.2174/138955711797247752.
Abstract
The 14-position of natural opiates (e.g. morphine) are unsubstituted, however synthetic approaches have uncovered that functionalizing position 14 gives rise to a wide range of diverse activities. This review focuses on SAR of the position, with the aim of aiding in the search for opioid analgesics with improved clinical profiles.
摘要
天然阿片类物质（例如吗啡）的 14 号位未被取代，然而，合成方法表明，在 14 号位进行官能团化会产生广泛的多样化活性。本综述重点介绍了该位置的 SAR，旨在帮助寻找具有改善临床特征的阿片类镇痛药。
相似文献
1
Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivatives.
Mini Rev Med Chem. 2011 Oct;11(12):1002-8. doi: 10.2174/138955711797247752.
2
Synthesis of 6,14-epoxymorphinan derivatives and their pharmacologies.
Bioorg Med Chem. 2011 Feb 1;19(3):1205-21. doi: 10.1016/j.bmc.2010.12.035. Epub 2010 Dec 21.
3
Novel 6β-acylaminomorphinans with analgesic activity.
Eur J Med Chem. 2013 Nov;69:786-9. doi: 10.1016/j.ejmech.2013.09.031. Epub 2013 Sep 22.
4
New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.
J Med Chem. 2006 Sep 7;49(18):5640-3. doi: 10.1021/jm0605785.
5
Synthesis and opiate receptor binding properties of 17-methyl-6,7-dehydro-3,14-dihydroxy-4,5alpha-epoxy-6,7:4',5'-pyrimidin omorphinans.
Bioorg Med Chem Lett. 1999 Dec 6;9(23):3375-80. doi: 10.1016/s0960-894x(99)00608-3.
6
Syntheses of 4,6'-epoxymorphinan derivatives and their pharmacologies.
Bioorg Med Chem. 2008 Apr 15;16(8):4304-12. doi: 10.1016/j.bmc.2008.02.082. Epub 2008 Feb 29.
7
Morphinan derivatives--A review of the recent patent literature.
IDrugs. 2003 Feb;6(2):129-37.
8
Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans.
Life Sci. 1999;64(22):2011-20. doi: 10.1016/s0024-3205(99)00148-4.
9
Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
Bioorg Med Chem. 2003 Sep 1;11(18):4143-54. doi: 10.1016/s0968-0896(03)00432-2.
10
Synthesis and evaluation of novel opioid ligands with a C-homomorphinan skeleton.
Bioorg Med Chem. 2016 May 15;24(10):2199-205. doi: 10.1016/j.bmc.2016.03.040. Epub 2016 Mar 25.
引用本文的文献
1
Peripheralization Strategies Applied to Morphinans and Implications for Improved Treatment of Pain.
Molecules. 2023 Jun 14;28(12):4761. doi: 10.3390/molecules28124761.
2
Recent Chemical and Pharmacological Developments on 14-Oxygenated--methylmorphinan-6-ones.
Molecules. 2021 Sep 18;26(18):5677. doi: 10.3390/molecules26185677.
3
Antinociceptive, Muscle Relaxant, Sedative, and Molecular Docking Studies of Peshawaraquinone Isolated from (Wall. ex G. Don) Steenis.
ACS Omega. 2021 Jan 4;6(1):996-1002. doi: 10.1021/acsomega.0c05720. eCollection 2021 Jan 12.
4
and Pharmacological Activities of 14--Phenylpropyloxymorphone, a Potent Mixed Mu/Delta/Kappa-Opioid Receptor Agonist With Reduced Constipation in Mice.
Front Pharmacol. 2018 Aug 31;9:1002. doi: 10.3389/fphar.2018.01002. eCollection 2018.
5
Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor.
Mol Pain. 2014 Jul 24;10:48. doi: 10.1186/1744-8069-10-48.
本文引用的文献
1
Synthesis of 14-alkoxymorphinan derivatives and their pharmacological actions.
Top Curr Chem. 2011;299:63-91. doi: 10.1007/128_2010_77.
2
14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.
Bioorg Med Chem Lett. 2009 Mar 15;19(6):1825-9. doi: 10.1016/j.bmcl.2008.12.093. Epub 2008 Dec 29.
3
New drug to restore bowel function approved under new FDA rules.
Am J Health Syst Pharm. 2008 Jul 1;65(13):1204. doi: 10.2146/news080052.
4
Mu opioid receptor antagonists: recent developments.
ChemMedChem. 2007 Nov;2(11):1552-70. doi: 10.1002/cmdc.200700143.
5
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.
J Med Chem. 2006 Aug 24;49(17):5333-8. doi: 10.1021/jm0604777.
6
Major increases in opioid analgesic abuse in the United States: concerns and strategies.
Drug Alcohol Depend. 2006 Feb 1;81(2):103-7. doi: 10.1016/j.drugalcdep.2005.05.009. Epub 2005 Jul 14.
7
Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities.
J Med Chem. 2005 May 5;48(9):3372-8. doi: 10.1021/jm040894o.
8
Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans.
J Clin Pharmacol. 2005 May;45(5):538-46. doi: 10.1177/0091270004273491.
9
Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence.
Ann N Y Acad Sci. 2004 Oct;1025:404-13. doi: 10.1196/annals.1316.050.
10
Antinociceptive and nociceptive actions of opioids.
J Neurobiol. 2004 Oct;61(1):126-48. doi: 10.1002/neu.20091.
Zotero 插件